Lubiprostone Sucampo Pharmaceuticals Takeda Pharmaceutical

被引：0
|
作者：
Winpenny, JP [1 ]
机构：
[1] Univ E Anglia, Sch Med, Biomed Grp, Inst Hlth, Norwich NR4 7TJ, Norfolk, England
来源：
IDRUGS | 2005年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing lubiprostone, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.
引用
收藏
页码：416 / 422
页数：7
相关论文
共 50 条
  • [41] Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
    Thomas Müller
    The European Journal of Health Economics, 2008, 9 : 1 - 3
  • [42] When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing
    Balderrama, Fanor
    Schwartz, Lisa J.
    Longo, Christopher J.
    HEALTH CARE ANALYSIS, 2020, 28 (02) : 121 - 136
  • [43] BIOCHEMICAL BASIS OF PHARMACEUTICAL CHEMISTRY .8. BIOLOGICAL MEMBRANE AS ACTION SITE OF PHARMACEUTICALS
    NUHN, P
    PHARMAZIE, 1990, 45 (09): : 700 - 710
  • [44] Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
    Mueller, Thomas
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (Suppl 1): : S1 - S3
  • [45] Pharmaceuticals in the environment (PIE) and the application of radiolabels to understand the environmental fate of active pharmaceutical ingredients
    Ryan, Jim J.
    Shipley, Nick
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (02): : 54 - 55
  • [46] How mandatory price reduction of reimbursed pharmaceuticals could result in increased pharmaceutical expenditure?
    Bacskai, M.
    Komaromi, T.
    Nagy, B.
    Kalo, Z.
    VALUE IN HEALTH, 2008, 11 (03) : A34 - A34
  • [47] Regulating the pharmaceutical industry - Having rationing rules for new pharmaceuticals but not other treatments is senseless
    Towse, A
    BRITISH MEDICAL JOURNAL, 1998, 316 (7126): : 227 - 227
  • [48] When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing
    Fanor Balderrama
    Lisa J. Schwartz
    Christopher J. Longo
    Health Care Analysis, 2020, 28 : 121 - 136
  • [49] Pharmaceuticals Market, Consumption Trends and Disease Incidence Are Not Driving the Pharmaceutical Research on Water and Wastewater
    Gonzalez Pena, Omar Israel
    Lopez Zavala, Miguel angel
    Cabral Ruelas, Hector
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (05) : 1 - 37
  • [50] Pharmaceutical Formulation Facilities as Sources of Opioids and Other Pharmaceuticals to Wastewater Treatment Plant Effluents
    Phillips, Patrick J.
    Smith, Steven G.
    Kolpin, D. W.
    Zaugg, Steven D.
    Buxton, Herbert T.
    Furlong, Edward T.
    Esposito, Kathleen
    Stinson, Beverley
    ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2010, 44 (13) : 4910 - 4916
12345